Filana Therapeutics plans Phase 2a simufilam trial in TSC-related epilepsy after FDA lifts clinical hold

By Public Technologies
  • Filana Therapeutics cleared to restart simufilam development in TSC-related epilepsy after the FDA lifted a clinical hold on its IND.
  • Patient screening for a Phase 2a proof-of-concept trial is expected to start in Q1 2027; no study results have been presented yet.
  • The 16-week randomized, double-blind study targets 40 patients ages 12 to 55 across 13 U.S. sites, with an optional 48-week extension.
  • Readout is expected to guide next-stage development decisions, including whether to expand into younger patient groups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006161), on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.